

4TH WORKSHOP ON HCV THERAPY ADVANCES NEW ANTIVIRALS IN CLINICAL PRACTICE

PARIS, FRANCE • 12 - 13 DECEMBER 2014

HCV THERAPY
ADVANCES

New Antivirals in
Clinical Practice

INVITATION

PROGRAM COMMITTEE



Charles Boucher, MD, PhD

Erasmus Medical Center Rotterdam
the Netherlands



Fred Poordad, MD

Texas Liver Institute/ University of Texas Health Science Center
USA



Stefan Zeuzem, MD

J.W. Goethe University Hospital Frankfurt
Germany

DEAR COLLEAGUES,

It is our great pleasure to announce the fourth edition of the Workshop on **HCV Therapy Advances – New Antivirals in Clinical Practice**, to be held in Paris, France on 12-13 December 2014.

Now that the second wave of DAAs are available or will become available in 2015, it becomes very important to identify which patients benefit more from which DAA. This year's program will focus on providing clinicians with the latest information, both published and presented at the AASLD in 2014, in order to give them guidance for optimal clinical management of their patients.

We are looking forward to meeting you in Paris in December 2014!

LEARNING OBJECTIVES

At the completion of this conference the participant will:

- Have an understanding of the basic concepts of HCV therapy
- Be updated on the latest developments in the field of HCV antiviral research
- Have an understanding of the challenges of HCV treatment in different patient populations
- Have an overview of the advantages and possibilities of new antivirals in HCV therapy
- Know how to apply Direct Acting Antivirals in clinical practice

TARGET AUDIENCE

The target audience of this workshop consists of healthcare professionals involved in daily care for HCV patients, infectious disease doctors, gastroenterologists, hepatologists and post-graduate students.

MEETING VENUE

Hotel Pullman Paris Tour Eiffel****
18 Avenue de Suffren
Paris, France



Registration and information: www.virology-education.com



PRELIMINARY PROGRAM

FRIDAY 12 DECEMBER

Presented Data 2014

- 13.00h *Registration & Lunch*
- 14.00h **Opening of the Workshop**
- 14.15h **Pivotal "New England Journal of Medicine" papers 2014 - Phase 3 Trial Data**
S. Zeuzem, MD
J.W. Goethe University Hospital Frankfurt, Germany



- 14.45h **News from AASLD - Nuke Regimens**
speaker to be confirmed

- 15.00h **News from AASLD - Non-Nuke Regimens**
M. Buti, MD, PhD
Hospital Vall' Hebron, Spain



- 15.15h **Discussion**
- 15.30h *Coffee Break*

16.00 h GILEAD - Satellite Symposium

Differential Benefits of DAA's in Different Patient Populations

17.00h In patients on a Waiting List for Liver Transplantation

The Data - R. Brown, MD, MPH
Columbia University New York, USA

The Clinic - R. de Knegt, MD, PhD
Erasmus Medical Center Rotterdam, the Netherlands



17.30h In HIV - HCV Coinfected Patients

The Data - K. Lacombe, MD, PhD
Saint - Antoine Hospital, Paris, France

The Clinic - S. Pol, MD, PhD
University of Paris V, France (tbc)



18.00h In Patients with Co-Morbidities

The Data - G. Dusheiko, MD
UCL Institute for Liver and Health, Royal Free Hospital, UK

The Clinic - *speaker to be confirmed*



- 18.30h **Adjournment for the Day**

SATURDAY 13 DECEMBER

- 09.30h **What is the Optimized Treatment Duration? To Overtreat versus Undertreat**

speaker to be confirmed

- 10.00h **Comparing the Different Guidelines (WHO/ EASL/AASLD)**
F. Poordad, MD
Texas Liver Institute / University of Texas Health Science Center, USA



- 10.30h **Panel Discussion - Country Specific Consideration of the Guidelines**
S. Zeuzem, MD - J.W. Goethe University Hospital Frankfurt, Germany



- 11.15h *Coffee Break*

- 11.45h **What Are the Critical Steps Needed for Global HCV Eradication**
H. Wedemeyer, MD
Hannover Medical School, Germany



- 12.15h **Discussion**

- 12.30h **Closure & Lunch**

Free registration for
young investigators
and
clinicians with
accepted clinical
cases!

WORKSHOP SPONSORS

Gold level sponsors:

abbvie  GILEAD

Principal supporter:



Bristol-Myers Squibb